Home Illustration

Omilancor, an oral LANCL2 agonist for the treatment of ulcerative colitis and Crohn's disease

BT-11, an oral LANCL2 agonist for the treatment of ulcerative colitis and Crohn’s disease

NX-13, an oral NLRX1 agonist for the treatment of ulcerative colitis and Crohn's disease

NX-13, an oral NLRX1 agonist for the treatment of ulcerative colitis and Crohn’s disease

PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis

PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis

We are committed to
the discovery and
development of
first-in-class, oral
therapeutics for
patients with
autoimmune disease

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. The Company’s lead product candidate, omilancor (BT-11), is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.

In January 2021, the Company reported initial results from its Phase 2 trial of omilancor for patients with mild-to-moderate ulcerative colitis (UC) and expects to initiate a Phase 3 trial in 2021. In May 2021, Landos initiated a Phase 2 trial of omilancor in a second indication – moderate-to-severe Crohn’s disease (CD).

View More

Reprogramming Immune Responses in Autoimmune Disease

Landos’ advanced AI-based integrated computational LANCE platform explores immune cell activity and metabolic function, a distinct approach that has verified two novel pathways currently in clinical development: LANCL2 and NLRX1. Activation of the LANCL2 pathway amplifies the immunosuppressive functions of T regulatory cells while decreasing production of inflammatory cytokines such as TNF-alpha. NLRX1, a second pathway discovered by Landos, provides a mechanism for modulating immune functions to complement or act in combination with other related treatments.

View More

Aiming to Bring Safer,
More Effective
Therapies to Patients
with IBD

For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. Landos’ therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune disease by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.

At Landos Biopharma, our mission is to
be bold and uncover new mechanisms of
treating autoimmune disease.

News

  • 5/6

    Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease
    Read More
  • 4/29

    Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis
    Read More
  • 4/26

    Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting
    Read More